For the purpose of investigating the clinical relevance of ZNF300 methylation in MDS and AML patients, the patients were divided into two groups (ZNF300 hypermethylated and non-hypermethylated) based on the cutoff value of 0.408 (set as “mean + 2 SD” in controls). This evidence concerns the gene ZNF300 and myelodysplastic syndrome.